Topic: therapeutic vaccines
Here is some other vaccine news of note for the week.
ImmusanT hopes Nexvax2 can help desensitize T cells responsible for autoimmune response in celiac disease.
China's ApolloBio increased upfront payment, while also terminating its right to buy into Inovio.
J&J's Janssen unit will shell out up to $879 million to develop HIV and HBV vaccines using Bavarian Nordic's MVA-BN technology.
Phase 2b data on Genocea's genital herpes vaccine is boosting confidence in the potential first-in-class shot.